57
Participants
Start Date
September 9, 2020
Primary Completion Date
December 14, 2021
Study Completion Date
May 31, 2022
Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
Soweto IMPAACT CRS, Johannesburg
Wits RHI Shandukani Research Centre CRS, Johannesburg
Umlazi CRS, Umlazi
Famcru Crs, Tygerberg
Siriraj Hospital, Mahidol University NICHD CRS, Bangkok
Chiangrai Prachanukroh Hospital NICHD CRS, Changklan, Muang
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai
Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago
Univ. of Colorado Denver NICHD CRS, Aurora
David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles
Lurie Children's Hospital of Chicago (LCH) CRS, Chicago
St. Jude Children's Research Hospital CRS, Memphis
Gaborone CRS, Gaborone
Molepolole CRS, Gaborone
Collaborators (1)
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
NETWORK
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute of Mental Health (NIMH)
NIH
ViiV Healthcare
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH